Journal Article Summary
The article examines the safety profile of semaglutide, a medication used for weight management, compared to a placebo in patients with cardiovascular disease and obesity. This research is significant because semaglutide has been shown to reduce major cardiovascular events, but understanding its long-term safety in a diverse population is crucial for both healthcare providers and patients. The SELECT study, which is the focus of this article, aims to provide comprehensive safety data that can inform treatment decisions for individuals at risk of cardiovascular issues.
In the SELECT study, 17,604 participants were randomly assigned to receive either semaglutide or a placebo, with a mean follow-up of nearly 40 months. The study found that serious adverse events (SAEs) were reported less frequently in the semaglutide group (33.4%) compared to the placebo group (36.4%). While there were more gallbladder-related disorders in the semaglutide group, no significant differences were observed in serious psychiatric disorders, acute pancreatitis, or malignant tumors between the two groups, indicating that semaglutide's safety profile aligns with previous studies.
Despite these positive findings, the study has limitations, including the exclusion of patients with certain health conditions, which may affect the generalizability of the results. Patients should discuss any concerns about semaglutide, especially regarding potential side effects like gallbladder issues or gastrointestinal symptoms, with their healthcare providers. It is essential to weigh the benefits of semaglutide against its risks, particularly for those with a history of gallbladder disease or other relevant health issues.
Medical Safety Note
This journal article summary is provided for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any medication.
Article Cited
- Kushner Robert F., Ryan Donna H., Deanfield John, Kokkinos Alexander, Cercato Cintia, Wilding John, Burguera Bartolome, Wu Chau‐Chung, et al.. Safety profile of semaglutide versus placebo in the SELECT study: a randomized controlled trial. Obesity (Silver Spring, Md.) 2025. DOI: 10.1002/oby.24222. PMID: 39948761. PMCID: PMC11897845.
Featured Pill Pals Product
Semaglutide with B-12 --- 10 mg / 2 mg / 4 ml --- 4 ml vial --- Weight Loss Glucagon-Like Peptide-1 (GLP-1)
Semaglutide with B-12 — 10 mg / 2 mg / 4 ml — 4 ml vial — Weight Loss Glucagon-Like Peptide-1 (GLP-1) is available through Pill Pals Pharmacy with cash-pay pharmacy pricing and free shipping where available. Prescription required.
Request a prescription transfer and our pharmacy team will help coordinate the next step.
